Another year of missed opportunity will pass by while other pipeline agents launch, uptake of BMS’ Zeposia potentially picks up,...
Author: Eric John BACKGROUND: After analyzing patient chart data from nearly 1,000 recently-initiated biologic/JAK inhibitor inflammatory bowel disease (IBD)...
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
By: Eric John Biosimilars to AbbVie’s Humira (adalimumab) first hit European markets in 2018, providing physicians with a lower-cost alternative...
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be...
By: Eric John Pandemic aside (if you can imagine that), launching a drug in the pharmaceutical industry is no walk...
In addition to a thorough evaluation of the current diagnosis and management of celiac disease (CeD), five pipeline product profiles...
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day...
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat,...
Spherix finds that perceptions related to efficacy appear to be impacting the new, more convenient formulation of the α4β7 integrin...
Aside from an in-depth evaluation of the current diagnosis and management of NAFLD/NASH, ten pipeline product profiles were evaluated by...
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
